Education
About Us
Working with TipRanks
Follow Us
Sinopharm Group Co Class H (HK:1099)
:1099
RESEARCH TOOLSreports
1099 Stock Chart & Stats
Day’s Range― - ―
52-Week RangeHK$16.02 - HK$23.65
Previous CloseN/A
Volume3.49M
Average Volume (3M)7.73M
Market Cap
HK$56.07B
Enterprise ValueN/A
Total Cash (Recent Filing)¥63.81B
Total Debt (Recent Filing)¥73.78B
Price to Earnings (P/E)7.3
Beta0.73
Next Earnings
Apr 25, 2025EPS Estimate
1.51Next Dividend Ex-Date
Jun 16, 2025Dividend Yield5.69%
Share Statistics
EPS (TTM)2.45
Shares Outstanding1,341,810,800
10 Day Avg. Volume4,656,401
30 Day Avg. Volume7,726,346
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.14
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$23.43Price Target Upside31.20% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
---
Sinopharm Group Co News
PremiumCompany Announcements
Sinopharm Reports Mixed Q1 2025 Financial Results
PremiumCompany Announcements
Sinopharm’s CNMDC Shows Resilient Financial Performance in Q1 2025PremiumCompany Announcements
Sinopharm Group Announces Board Meeting to Review Q1 2025 Results
PremiumCompany Announcements
Sinopharm Accord Reports Significant Profit Decline in 2024
PremiumCompany Announcements
Sinopharm Group’s 2024 Transformation and Innovation Drive
PremiumCompany Announcements
Sinopharm Group Announces Final Dividend for 2024
PremiumCompany Announcements
Sinopharm Group Reports Challenging 2024 Financial Results---
Bulls Say, Bears Say
Bulls Say
Market PositionContinuous market share gains from industry consolidation could make Sinopharm remain the largest drug distributor in China and expand its market share significantly.
Operational EfficiencyA new policy allows medical institutes to apply for funds for payment to suppliers in advance, speeding up pharm distributor payments.
Bears Say
Earnings Performance1H24 earnings dropped by 10% y/y, below expectation.
---
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
13.79%
Mutual Funds
― Other Institutional Investors
76.80% Public Companies and
Individual Investors
1099 FAQ
What was Sinopharm Group Co Class H’s price range in the past 12 months?
Sinopharm Group Co Class H lowest stock price was HK$16.02 and its highest was HK$23.65 in the past 12 months.
What is Sinopharm Group Co Class H’s market cap?
Sinopharm Group Co Class H’s market cap is HK$56.07B.
When is Sinopharm Group Co Class H’s upcoming earnings report date?
Sinopharm Group Co Class H’s upcoming earnings report date is Apr 25, 2025 which is tomorrow.
How were Sinopharm Group Co Class H’s earnings last quarter?
Sinopharm Group Co Class H released its earnings results on Mar 23, 2025. The company reported HK$0.604 earnings per share for the quarter, missing the consensus estimate of HK$1.499 by -HK$0.895.
Is Sinopharm Group Co Class H overvalued?
According to Wall Street analysts Sinopharm Group Co Class H’s price is currently Undervalued.
Does Sinopharm Group Co Class H pay dividends?
Sinopharm Group Co Class H pays a Annually dividend of HK$0.729 which represents an annual dividend yield of 5.69%. See more information on Sinopharm Group Co Class H dividends here
What is Sinopharm Group Co Class H’s EPS estimate?
Sinopharm Group Co Class H’s EPS estimate is 1.51.
How many shares outstanding does Sinopharm Group Co Class H have?
Sinopharm Group Co Class H has 1,341,810,800 shares outstanding.
What happened to Sinopharm Group Co Class H’s price movement after its last earnings report?
Sinopharm Group Co Class H reported an EPS of HK$0.604 in its last earnings report, missing expectations of HK$1.499. Following the earnings report the stock price went down -6.262%.
Which hedge fund is a major shareholder of Sinopharm Group Co Class H?
Currently, no hedge funds are holding shares in HK:1099
---
Sinopharm Group Co Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
HK$23.43 (31.20% Upside)
HK$23.43 (31.20% Upside)
Blogger Sentiment
Neutral
HK:1099 Sentiment 50%
Sector Average 70%
Sector Average 70%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-17.62%
12-Months-Change
Fundamentals
Return on Equity
9.19%
Trailing 12-Months
Asset Growth
-0.45%
Trailing 12-Months
Company Description
Sinopharm Group Co Class H
Sinopharm Group Co. Ltd., together with its subsidiaries, engages in the wholesale and retail of pharmaceutical and medical devices and healthcare products in the People's Republic of China. The company operates through four segments: Pharmaceutical Distribution, Medical Devices, Retail Pharmacy, and Other Business. The Pharmaceutical Distribution segment distributes pharmaceutical products to hospitals, other distributors, retail drug stores, and clinics. This segment also offers distribution, logistics, and other value-added services for domestic and international pharmaceutical and healthcare products manufacturers, and other suppliers. The Medical Devices segment distributes medical devices. The Retail Pharmacy segment operates and franchises a network of retail drug stores. As of December 31, 2021, this segment had 10,259 retail pharmacies. The Other Business segment engages in the production and sale of pharmaceutical products, chemical reagents, and laboratory supplies. The company also rents and manages properties; distributes medical instruments, Chinese herbal medicines, antibiotics, and biological products; and offers information technology development and medicine consultation, investment, goods and technology import and export, business consultation, health consultation, medical consultation, market information consultation and investigation, and convention and exhibition services. In addition, it manages medical project investment, consulting, and technology training activities. Sinopharm Group Co. Ltd. has a strategic partnership with I-Mab to enhance its commercial capabilities and commercialization transformation. The company was founded in 2003 and is headquartered in Shanghai, the People's Republic of China. Sinopharm Group Co. Ltd. is a subsidiary of Sinopharm Industrial Investment Co., Ltd.
---
1099 Stock 12 Month Forecast
Average Price Target
HK$23.43
▲(31.20% Upside)
Technical Analysis
Ping An Insurance Company of China
―
Sino Biopharmaceutical
―
CSPC Pharmaceutical Group
―
China Medical System Holdings
―
China Resources Pharmaceutical Group Ltd.
―
Best Analysts Covering 1099
1 Year
1 Year Success Rate
0/7 ratings generated profit
1 Year Average Return
-15.94%
reiterated a buy rating last month
Copying Jialin Zhang's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -15.94% per trade.
---